Companies in #Non-Small Cell Lung Cancer (NSCLC)
Found 2 companies operating in this sector.
Nuvalent is a clinical-stage biopharmaceutical company developing small-molecule kinase inhibitors for oncology, with a particular focus on designing brain-penetrant, resistance-selective compounds. Its lead programs target ROS1 and ALK in non-small cell lung cancer, with additional programs in HER2 and KRAS. The company has positioned its chemistry platform to address the dual challenges of kinase resistance and CNS metastases, and in June 2026 signed a partnership with GSK giving GSK ex-US rights to two of its kinase inhibitors in a deal structured to take advantage of a post-ASCO share-price dip.
Summit Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for serious unmet medical needs, with a leading oncology asset ivonescimab (a PD-1/VEGF bispecific antibody) in-licensed from Akeso for global development.